<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143685</url>
  </required_header>
  <id_info>
    <org_study_id>MISOX-001</org_study_id>
    <nct_id>NCT04143685</nct_id>
  </id_info>
  <brief_title>Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes</brief_title>
  <official_title>Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sammour.rami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the rate of vaginal delivery after induction of labor with misoprostol
      versus oxytocin in women with prelabor rupture of membranes. Participants will be randomized
      to receive either oral misoprotsol every four hours until going into labor, or intravenous
      oxytocin in increasing dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Misoprostol is a synthetic prostaglandin analogue commonly used for labor induction. It
      causes uterine contractions and ripening of the cervix. Oxytocin sold under the brand name
      Pitocin among others, is a medication made from the peptide oxytocin and is used to cause
      contraction of the uterus to start labor.

      This randomized controlled trial will compare induction of labor in women with term premature
      rupture of the membranes and unripe cervix using misoprostol versus oxytocin. The primary
      outcome is the rate of vaginal delivery. Secondary outcomes will include cesarean section
      rate, time interval from induction of labor to delivery, neonatal morbidity, patient
      satisfaction and side effects, as well as chorioamnionitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal delivery rate</measure>
    <time_frame>During delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative delivery rate, Cesarean section rate, time interval from induction of labor to delivery</measure>
    <time_frame>During delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chorioamnionitis rate</measure>
    <time_frame>During or after delivery up to 7 days</time_frame>
    <description>intra-amniotic infection during or after delivery representing in possible combination of maternal fever, fetal tachycardia, maternal leukocytosis, Histopathologic evidence of infection or inflammation or both in the placenta, fetal membranes, or the umbilical cord vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine tachysystole</measure>
    <time_frame>During delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>After delivery until discharge</time_frame>
    <description>Apgar score, , ,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>immediately after delivery</time_frame>
    <description>Umbilical Cord Blood Gases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>up to 7 days after delivery</time_frame>
    <description>NICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>up to 7 days after delivery</time_frame>
    <description>Antibiotic administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prelabor Rupture of Membranes</condition>
  <condition>Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Oral administration of cytotec every 4 hours until a maximum of 6 doses</description>
    <arm_group_label>misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
    <other_name>PGE1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intravenous infusion of Pitocin through an IVAC until delivery</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in their 1st - 4th delivery

          -  Term prelabor rupture of membranes (37+0 to 42+0 gestational age)

          -  Vertex presentation

          -  Singleton pregnancy

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Previous cesarean section

          -  Chorioamnionitis on admission

          -  &gt;2 symptomatic uterine contractions in 10 minutes

          -  Prostaglandins hypersensitivity

          -  Contraindication for vaginal delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rami Sammour, MD</last_name>
      <phone>+97248359052</phone>
      <email>rsammour2002@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bnai Zion Medical Center</investigator_affiliation>
    <investigator_full_name>sammour.rami</investigator_full_name>
    <investigator_title>Head of Obstetrics</investigator_title>
  </responsible_party>
  <keyword>PROM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

